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Rationale: Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) in combination with 
CRISPR/Cas9 genome editing provide unparalleled opportunities to study cardiac biology and disease. However, 
sarcomeres, the fundamental units of myocyte contraction, are immature and nonlinear in hiPSC-CMs, which 
technically challenge accurate functional interrogation of contractile parameters in beating cells. Furthermore, 
existing analysis methods are relatively low-throughput, indirectly assess contractility, or only assess well-aligned 
sarcomeres found in mature cardiac tissues.
Objective: We aimed to develop an analysis platform that directly, rapidly, and automatically tracks sarcomeres in 
beating cardiomyocytes. The platform should assess sarcomere content, contraction and relaxation parameters, 
and beat rate.
Methods and Results: We developed SarcTrack, a MatLab software that monitors fluorescently tagged sarcomeres 
in hiPSC-CMs. The algorithm determines sarcomere content, sarcomere length, and returns rates of sarcomere 
contraction and relaxation. By rapid measurement of hundreds of sarcomeres in each hiPSC-CM, SarcTrack 
provides large data sets for robust statistical analyses of multiple contractile parameters. We validated 
SarcTrack by analyzing drug-treated hiPSC-CMs, confirming the contractility effects of compounds that directly 
activate (CK-1827452) or inhibit (MYK-461) myosin molecules or indirectly alter contractility (verapamil and 
propranolol). SarcTrack analysis of hiPSC-CMs carrying a heterozygous truncation variant in the myosin-
binding protein C (MYBPC3) gene, which causes hypertrophic cardiomyopathy, recapitulated seminal disease 
phenotypes including cardiac hypercontractility and diminished relaxation, abnormalities that normalized with 
MYK-461 treatment.
Conclusions: SarcTrack provides a direct and efficient method to quantitatively assess sarcomere function. By 
improving existing contractility analysis methods and overcoming technical challenges associated with functional 
evaluation of hiPSC-CMs, SarcTrack enhances translational prospects for sarcomere-regulating therapeutics 
and accelerates interrogation of human cardiac genetic variants.  (Circ Res. 2019;124:1172-1183. DOI: 10.1161/
CIRCRESAHA.118.314505.)
Key Words: cardiomyocyte contractility ◼ cell imaging ◼ hypertrophic cardiomyopathy ◼ induced pluripotent stem 
cells ◼ MYK-461 ◼ myosin binding protein-C ◼ sarcomeres
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Recent technical breakthroughs in pluripotent stem cell tech-nologies1 and CRISPR/Cas9 genome editing2 have enabled 
the production of human cardiomyocytes from induced pluri-
potent stem cells (human induced pluripotent stem cell–derived 
cardiomyocytes [hiPSC-CMs]) with patient-specific genotypes. 
Unlike primary cultures of human cardiomyocytes that are diffi-
cult to obtain and maintain, hiPSC-CMs can be mass-produced 
using protocols that are optimized for 2-dimensional or 3-di-
mensional differentiation.3 Moreover, CRISPR/Cas9 genome 
editing of hiPSC lines with isogenic backgrounds ensures that 
an observed downstream phenotype reflects the variant under 
study. Although hiPSC-CMs are often genetically, structurally, 
and metabolically immature in comparison to endogenous a-
dult cardiomyocytes, evolving methods to pattern4 and improve 
maturation5 continue to advance the utility of hiPSC-CMs. 
Studies of hiPSC-CMs have already contributed insights into 
cardiomyocyte biology,6 heart disease mechanisms,7,8 and have 
uncovered off-target cardiotoxic drug effects.9,10
A critical component of functional analyses of cardiomyo-
cytes is the assessment of dynamic contraction in beating cells. 
Existing methods assess contraction by imaging cardiomyocyte 
movement using edge detection, changes in pixel intensities a-
cross image frames,11,12 or, optical flow-based displacement.13 
Other methods directly monitor changes in sarcomere length 
(SL) by fast Fourier transform (FFT)14 analysis, 2-photon 
microscopy,15 user-selected sarcomeres that are tagged by fluo-
rescence16 or quantum dots conjugated to antibodies that target 
sarcomere proteins.17 These approaches vary with regards to user 
input, requirements for specialized equipment, and throughput 
speed, but most output average signals, often using FFT analy-
ses, and are most often applied to well-ordered sarcomeres. 
Averaging FFT signals is most appropriate for evaluating ho-
mogenous populations of cardiomyocytes with linearly aligned 
sarcomeres that consistently and equally contract. However, 
the application of these methodologies to study hiPSC-CMs is 
challenged by their circular morphology and heterogeneity in 
differentiation and maturation. The orientation of sarcomeres 
in hiPSC-CMs is variable and contraction is nonlinear, which 
results in significant cell-to-cell variability.9 Customized strate-
gies to pattern hiPSC-CMs addresses some of these issues,18 but 
these platforms add other variables (eg, matrix stiffness) that can 
impact contractility and also delay experimental throughput.4
To address these hurdles, we developed SarcTrack, a 
rapid, easily implemented MatLab algorithm that directly 
monitors absolute sarcomere count and dynamic changes in 
SL, providing parameters for sarcomere content, percent con-
traction, sarcomere contraction and relaxation durations, and 
cellular beat rate (Figure 1). These measures are obtained di-
rectly from videos of fluorescently labeled Z-disc or M-line 
pairs (Online Figure I) within each sarcomere and define the 
mechanics of contraction at the level of the single sarcomere. 
The analysis of hundreds of sarcomeres per cell provides en-
hanced statistical power for evaluating contractility across the 
full cardiac cycle. Using fluorescent tracking of sarcomeres 
using SarcTrack, we gained direct insight into pharmaco-
logical effects on individual sarcomere function that can be 
extended to subpopulations of sarcomeres within a cell. By 
contrast, techniques using bright-field microscopy are limited 
in providing averaged cellular contractile function.11,12
Methods
The data that support the findings of this study are available from the 
corresponding authors on reasonable request.
Nonstandard Abbreviations and Acronyms
FFT fast Fourier transform
GFP green fluorescent protein
HCM hypertrophic cardiomyopathy
hiPSC-CMs human induced pluripotent stem cell–derived cardiomyocytes
MyBPC myosin-binding protein C




• Many cardiovascular diseases and pharmacological agents alter cel-
lular contractility.
• Human induced pluripotent stem cell–derived cardiomyocytes provide 
a human model for screening variants that may cause disease and 
compounds that may alter cardiomyocyte functions.
• Tools are limited that provide automated, high-fidelity, and direct as-
sessments of sarcomeres, the contractile unit within human induced 
pluripotent stem cell–derived cardiomyocytes.
What New Information Does This Article Contribute?
• SarcTrack provides an automated platform to identify and monitor con-
tractile function in vast numbers of individual single sarcomeres within 
human induced pluripotent stem cell–derived cardiomyocytes.
• SarcTrack reliably detects aberrant sarcomere function caused by 
human gene variants, pharmacological agents, and novel small mol-
ecules that modulate sarcomere activity.
• SarcTrack, together with tools for genetic engineering, allows efficient 
functional analyses of human gene variants, including those of un-
known significance, and provides a robust screening platform to as-
sess potential therapeutic compounds.
SarcTrack provides a high-fidelity and high-throughput approach 
to quantify sarcomere contractility in human induced pluripotent 
stem cell–derived cardiomyocytes. Applying this technique, we 
demonstrate that SarcTrack reliably defined basal contractility 
and relaxation as well as changes in these parameters in re-
sponse to pharmacological agents or human gene variants that 
cause hypertrophic cardiomyopathy.
Editorial, see p 1146 
In This Issue, see p 1141 
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TTN-GFP and MYOM1-RFP Fluorescent 
Sarcomere Reporter hiPSC Lines and 
Differentiation Into hiPSC-CMs
SarcTrack analyzes hiPSC-CMs with fluorescent tags on sarco-
mere proteins. We previously reported protocols to introduce GFP 
(green fluorescent protein) onto the Z-disc protein titin (TTN-
GFP) in hiPSCs.19 Paralleling this approach, we used CRISPR/
Cas9-mediated homology-directed repair of hiPSCs to introduce 
RFP (red fluorescent protein) onto the carboxyl terminus of myo-
mesin-1 (MYOM1-RFP), an M-band protein (Online Figures I 
through III). Appropriate targeting was confirmed by DNA se-
quencing. Undifferentiated tagged hiPSCs lack fluorescence, but on 
differentiation into hiPSC-CMs,3 sarcomeres fluoresce, from which 
sarcomere periodicity can be assessed.20
For SarcTrack analyses, fluorescent-tagged hiPSC-CMs (<20-
day postdifferentiation) were replated onto imaging-optimized 12-
well plates (or 96-well plate for drug treatments, MatTek) containing 
1:100 Matrigel (Corning) in RPMI 1640 medium. Two days after 
replating, cells were returned to RPMI 1640 containing B27 sup-
plement, with insulin, which is changed every 2 days. Imaging was 
performed at day 30 postdifferentiation of hiPSC-CMs, a commonly 
used time point for functional analyses.10
Figure 1. Using SarcTrack to identify fluorescent sarcomeres. A, Initial parameters are defined on a single frame of an acquired image stack to test 
fitting of Z-discs by SarcTrack wavelets. Wavelet parameters include the wavelet dimensions (d, e, f), the df for fitting the wavelet in certain orientations (α, 
the angles around c), and the definition of the grid points when performing the convolution for fitting the wavelets to fluorescent Z-disc pairs (hopsize and 
halfwindowsize). Once parameters are defined (see Online Methods), dwProcessFrame can be run to visualize the goodness of wavelet fitting to a specific 
frame. This process is repeated to find the best parameters for labeling Z-discs. In this example, we show a highly disordered cell with significant out of 
focus fluorescence to demonstrate the ability of these parameters to be adapted to robustly define true Z-disc pairs. B, Once parameters have been defined 
and tested on a single frame a stack can be analyzed using dwProcessFolder. This process allows the user to deposit one stack into a folder for analysis 
and this provides 4 outputs. A folder containing each individual frame fit with marked wavelets to check fidelity of wavelet fitting, DWPrdFrq providing the 
period and frequency of beating defined by sinusoidal fitting of the contractile functions, DWDists providing the distance (d, in pixels) of each wavelet pair 
for each frame of the stack. DWStats provides the precalibrated raw values derived from the sawtooth fitting of contractile cycles of each sarcomere tracked 
including contraction time (frames), relaxation time (frames), the minimum distance between wavelets, and the maximum distance between wavelets (pixels). 
dwCheckResults will output graphs of these parameters and show the fitting of the sinusoid and sawtooth for the combined sarcomere contractility of the 
entire field of view (FOV). C, Once parameters have been set and quality control of data has been approved using dwCheckResults one can run a folder of 
multiple movies. A computing cluster can be used to run many movies in parallel, and by using 4 cores, users can analyze 5-second movies every 40 min 
with parallel batches of up to 100 movies at a time. Once movies are batch analyzed, a script is applied to convert the outputs from DWStats to microns 
and seconds from pixels and frames. A mean and SEM is obtained from each DWStats file and data is output into a single .txt file. This script also adds 
the number of sarcomeres tracked in each movie as a separate column to all other parametric means and errors. This workflow ensures that the user can 
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Infection of hiPSC-CMs With mApple-ACTN-2 
Lentivirus
SarcTrack can assess hiPSC-CMs with fluorescent tags that are deliv-
ered by lentivirus (5 μL of viral stock in 2 mL of RPMI+B27+Insulin, 
to achieve a viral multiplicity of infection ≥1), such as mApple-
ACTN-2 lentivirus.6 After 24 hours of incubation, infected cells were 
washed with PBS and replaced with fresh RPMI 1640+B27+Insulin 
medium. The mApple-ACTN-2 signal was apparent within 2 to 3 
days of adding virus.
Generation and Functional Analysis of Heterozygous 
MYBPC3 Loss-of-Function hiPSC-CMs
Using CRISPR/Cas9 editing, we used a guide RNA21 to introduce a 
frameshift variant into exon-2 of the MYBPC3 gene in TTN-GFP hiP-
SCs. Subclone analyses yielded an 8-nucleotide deletion in one allele, 
which was confirmed by DNA sequencing. Mutant MYBPC3 lines 
readily differentiated into hiPSC-CMs3 and are denoted MyBPCt/+ 
(myosin binding protein-C) TTN-GFP hiPSC-CMs. Control TTN-
GFP hiPSC-CM line underwent nucleofection without guides and 
maintained normal, biallelic MYBPC3 expression.
Small Molecules and Drug Treatment on hiPSC-
CMs
Small molecules (verapamil and propranolol obtained from Sigma 
Aldrich, MYK-461 from Cayman Chemical, and CK-1827452 from 
Selleck Chemicals) were dissolved in water or DMSO (10 mmol/L) 
and stored at −80°C. hiPSC-CMs (day 30 postdifferentiation) were 
treated in 96-well imaging plates with compounds diluted in RPMI 
1640 plus B27 and insulin medium to achieve half-log doses ranging 
from 0 to 10 μmol/L final concentrations unless otherwise specified. 
When sequential increasing doses of a compound (200 μL) was de-
livered to 96-well imaging plates containing hiPSC-CMs, plates were 
equilibrated at 37°C and 5% CO
2
 for 1 hour before imaging.
Traction Force Microscopy on Hydrogels
Micropatterned fibronectin polyacrylamide hydrogel substrates were 
fabricated as described.4 Polyacrylamide gels of 7.9 KPa stiffness 
were made by adjusting the concentrations of acrylamide and bi-
sacrylamide stock solution (Bio-Rad Laboratories, Hercules, CA), as 
described.22
The contractile forces exerted by hiPSC-CMs on the gel sub-
strates were computed by measuring the displacement of fluorescent 
beads embedded within the gel as described.6 hiPSC-CMs were elec-
trically paced at 1 Hz, and videos of bead motion near the substrate 
surface, distributed in and around the contact region of a single cell, 
were acquired at a frame rate of 30 frames per second. The stress 
vector fields were generated using an open source package of Fiji 
plugins23 and were interpolated with a custom MatLab script. Root 
mean squares of the magnitudes of single cell stress vectors were 
computed using the formula:
Root mean squares of the magnitudes of single cell stress vect
ors=√1(|S1|2+|S2|2+…+ |Sn|2), in which Sn is a single stress vec-
tor. Root mean squares of the magnitudes of single cell stress vec-
tors were plotted over time and smoothed using a custom MatLab 
script. Contractile stress was calculated as the difference between 
local maximum and minimum root mean squares of the magnitudes 
of single cell stress vectors and was averaged over 3 to 4 beat periods 
for each cell.
hiPSC-CM Video Acquisition and Data Processing
Five-second video imaging was conducted on small hiPSC-CM 
clusters of 2 to 4 cells maintained at 32°C to 37°C and 5% CO
2
, us-
ing a 100X objective of a fluorescent microscope with a minimum 
acquisition rate of 30 frames per second. Pacing, where specified, 
was conducted at 1 Hz using a manual electrode. For downstream 
evaluation of contractility videos, SarcTrack was run on the Harvard 
Medical School high-performance computing cluster. Data process-
ing required on average 4 CPU cores to analyze a 5-second video in 
15 to 20 minutes.
Mathematical Foundations for SarcTrack-Based 
Sarcomere Tracking
The SarcTrack algorithm (provided on GitHub at https://github.com/
HMS-IDAC/SarcTrack) modeled each sarcomere as a double wavelet, 




 (Figure 1A), with 
distance d between wavelet peaks (eg, peak fluorescence intensity of 
the sarcomere), center of mass c (eg, the midpoint between wavelet 
peaks), and α, the rotation of the wavelet pair around c. The user 
specifies these parameters, as detailed in Online Methods. A single 
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Here σ α δ, , ,s corresponded to scale, angle (in radians), displacement 
(offset from zero), and stretch of the wavelet, respectively.
We then defined a double wavelet as , , / , , /w n r w wd d= +( )( )−α σ σ0 2 0 2 , 
where r was a rotation by angle α and n was a normalization that 
ensures the double wavelet has mean 0 and norm 1. This resulted in 
simply adding 2 single parallel wavelets at distance d, rotating the 
result by an angle α, then normalizing.
Each video frame was convolved with a bank of double-wavelet 
kernels, including kernels for a wide and dense enough set of dis-
tances d, and a dense enough set of angles α. The range of distances 
was determined by measuring the distances between Z-discs on sev-
eral frames. The density of distances and angles was determined em-
pirically, based on visual comparison between images and detection 
outputs. The stretch (elongation) and scale of each individual Morlet 
wavelet were estimated by analyzing z-disc cross-sections, and the 
detection outputs.
The bank of double wavelets was given by 
B w d d dP Q d P Q, , : ,..., , ,...,= = ={ }α α α α1 1 , where P,Q were the number 
of different distances and angles, respectively. After convolving a 
frame F with each wavelet in B
P,Q
, the results were a stack of images 
S F w w BP Q d d P Q, , , ,* := ∈{ }α α , where * was the convolution operator.
After convolutions, a subgrid of pixels was defined. For each 
pixel in the subgrid, the maximum filtering output was located in a 
small neighborhood of the pixel, and the angle and distance of the 
double wavelet of maximum output were recorded. That is, for a 
location p, in the subgrid, the optimal distance d and angle α were 
computed as ˆ ˆ, *, , ,d p argmax F w pd dα α α( ) = +( )ε ε  for ε  in a small 
neighborhood or zero. This neighborhood should be small enough 
so that p qp q+ ≠ +ε ε for all ε εp q, in the neighborhood and p,q adjacent 
grid points (Figure 1A; convolution of wavelet fitting).
After this step, we had a set of pixel locations, with correspond-
ing angles, distances, and magnitudes of best-fitting double wavelets. 
Although for SarcTrack analyses, we are particularly interested in 
distances, the angles and magnitudes were useful for reconstructing 
the image to verify proper fitting. Intuitively, each point of the sub-
grid should contain a double-wavelet structure that is allowed to snap 
into the nearest sarcomere by changing d, c, and α until a good fit 
was reached (Figure 1A; convolution of wavelet fitting). This strategy 
reasonably assumed continuity in both the time in which neighbor-
ing sarcomeres contract, and the distance between their Z-discs. This 
model allowed us to probe for local distance between Z-discs over 
subsequent frames created by process folder and output into .csv files 
(Figure 1B).
After detecting sarcomeres and removing those of low magnitude, 
visualization of the curve of average distances using CheckResults 
showed a sawtooth periodic function, akin to adult cardiomyocyte 
contraction (Figure 1B). Because we were not only interested in max-
imum and minimum distances between Z-discs, but also contraction 
and relaxation times, we fitted this curve with a custom-designed pe-
riodic curve that was constant for areas corresponding to a relaxed 
sarcomere and had a nonlinear sawtooth-shaped valley for contrac-
tion and relaxation intervals.
Let ρc r x
ifx c x c if c x
x r if x r ifx r,
, / ,
/ ,
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The periodic curve we fitted to the tracked distances of each 
sarcomere was defined as s x s xc r c r, ,’ /( ) = ( ) +( )( ) −2 1 2 12 , where 
s x xc r r c’ , ,( ) = +( )( ) −( )ρ π π πmod2 .
Fitting was performed by optimizing the correlation between 
the raw distance data d t( ) and as ftr c, +( )δ , where t is the time pa-
rameter (or frame index), f is the frequency, a is the amplitude, and 
δ the offset. Only parameters c (contraction), r (relaxation), and 
δ were optimized for each sarcomere independently. Parameters 
f and a were precomputed by estimating the period/frequency of 
the averages of d(t) using a simpler model that fits a sinusoidal 
function.
To initialize the optimization algorithm that fitted the average-
distance curve, we first estimated the curve’s period/frequency us-
ing a simpler model that fits a sinusoidal function (Figure 1B). This 
gave an initial approximation for the contraction and relaxation 
times. However, because sarcomeres do not contract and relax in 
synchrony, the averaging process overestimated those times. Thus, 
we independently fitted each curve of selected sarcomeres, using the 
average fit parameters as starting values in the optimization routine.
Finally, we used a measure of goodness of fit (root mean square 
error) between raw curves and fitted models to further select sarco-
meres and improve the statistical robustness of reported results. To 
the best of our knowledge, the independent measurement of contrac-
tion/relaxation times per sarcomere has not been done, and previous 
methods have not taken account for asynchronous oscillations in 
sarcomeres.
Once these results were checked for fidelity, we applied these 
tested parameters for sarcomere tracking in multiple movies 
(Figure 1C). By performing tandem analyses using a computer clus-
ter (or computer with multiple processor cores), movies were simul-
taneously analyzed. Once completed, we applied a custom script to 
collate the mean and SEM24 for each analyzed field of view from a 
movie, which was reported as an individual row in a single .txt file 
(Figure 1C).
Production of Synthetic Sarcomeres for SarcTrack 
Benchmarking
The algorithm for generating synthetic sarcomeres is deposited on-
line (https://github.com/HMS-IDAC/SarcTrack). Synthetic movies 
were generated by placing parallel single wavelets at predefined dis-
tances. We generated movies with 5 lines of 9 wavelets each.
The distances between wavelets changed over time according to 
the sawtooth function defined in the methods for SarcTrack. Half of 
the synthetic sarcomeres contraction cycle was delayed to test how 
the algorithm coped with asynchronous contraction cycles. Because 
we knew the parameters that generate the distances (eg, minimum 
and maximum distance between wavelets, contraction, and relaxation 
times), we confirmed that the algorithm properly identifies synthetic 
sarcomeres.
Statistics
Where single statistical comparisons were applied, a Student t test 
was used with a significance cutoff of P<0.05. Where multiple 
comparisons were made, ANOVA was used with multiple compari-
sons tested by post hoc Bonferroni correction with a statistical sig-
nificance cutoff of P<0.05. All significances are stated in the text 
with the corresponding P value. All data are stated as mean with 
SEMs.24
Results
SarcTrack was designed to image (Online Figure I) fluores-
cently labeled sarcomeres in hiPSC lines19,20 such as lines with 
endogenous GFP-tags on titin (TTN-GFP; Online Figure II) 
or myomesin (MYOM1-RFP; Online Figure III). Cells can 
be exogenously labeled, using lentivirus with cargo such as 
ACTN-2 labeled with mApple (Online Figure IB).6 hiPSCs 
with fluorescently tagged sarcomere genes exhibited no 
alterations in pluripotency in comparison to untagged isogenic 
hiPSCs (Online Figure IV). On differentiation into hiPSC-
CMs fluorescence microscopy (100X oil immersion objective) 
showed localized fluorescence at specific sarcomere domains: 
Z-discs tagged by TTN-GFP and ACTN-2-mApple labeled 
Z-discs and M-band tagged by MYOM1-RFP (Online Figure 
IB). An illustration of how contraction and relaxation times 
were delineated, as well as representative traces of tracked 
sarcomeres in paced and unpaced states are shown in Online 
Figure IC and ID. Differentiation of the TTN-GFP reporter 
hiPSC line into skeletal muscle fibers25–27 (Online Figure V), 
demonstrated the utility of these lines to label skeletal muscle 
sarcomeres for SarcTrack analyses.
SarcTrack employs a MatLab algorithm (see Methods and 
Online Methods) that fitted individual sarcomeres as a pair of 




) with distance d between 
crests, center of mass c, and orientation α (Figure 1A). After 
removing sarcomeres of low fluorescence intensity, SarcTrack 
detected real-time distances between sarcomere domains (eg, 
Z-discs or M-lines in Figure 1B). The algorithm assumes con-
tinuity in the time in which neighboring sarcomeres contract, 
and the distance between labeled domains, and assesses the 
maximum and minimum distances between Z-discs (or an-
other sarcomere domain). To detect the duration of contrac-
tion and relaxation, individual sarcomeres were each fitted 
to a custom-designed periodic curve that accounts for asyn-
chronous contraction and relaxation (Figure 1B). Over 200 
sarcomeres in each microscopic field of view were imaged to 
obtain data sets for calculation of specific contractile param-
eters (Figure 1C).
To test the fidelity of this system we constructed synthetic 
computer generated sarcomeres (Figure 2A through 2D). 
Simulated Z-discs were generated with known pixel distanc-
es from their nearest neighbor (Figure 2A; Online Movie I). 
SarcTrack easily identified the simulated Z-discs (Figure 2B). 
We simulated asynchronous contraction in 2 different states: 
(1) initially where contraction and relaxation durations were 
identical (Figure 2C); or (2) where relaxation was modeled as 
twice the length as contraction (Figure 2D). The SarcTrack al-
gorithm correctly measured these prescribed contraction and 
relaxation rates (Figure 2C and 2D).
Additionally, we benchmarked SarcTrack against an FFT 
method of sarcomere detection (SarcOptiM).14 FFT analysis 
was not intended for nonlinear sarcomeres as exist in hiPSC-
CMs, which impeded image analysis (Figure 2E), as only 
a few rows of sarcomeres (marked in red) could be used in 
each field of view. In contrast, SarcTrack could reliably mark 
individual sarcomeres in each field of view irrespective of 
orientation (Figure 2F). Moreover, the requirement for lin-
ear arranged sarcomeres limits the number of samples within 
a field of view that are appropriate for analyses, which re-
duces the overall data set. For example, using FFT analyses 
we measured 4±2 sarcomeres across 3 movies (Figure 2G), 
and overall 13 sarcomeres with an average contractility of 
7.5±0.7%. By contrast, SarcTrack measured 496±160 sar-
comeres across these 3 movies and overall 1489 sarcomeres 
with an average contractility of 10±0.01% (Figure 2G). 
After applying a compound to decrease cellular contractility 
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per movie with a mean contractility of 3.2±0.5% (n=9 sar-
comeres), whereas SarcTrack measured a mean of 273±35 
sarcomeres with a mean contractility of 3.8±0.06% (n=820 
sarcomeres; Figure 2H).
To assess whether tagged sarcomeres altered function, 
we first performed traction stress analyses of TTN-GFP and 
untagged isogenic hiPSC-CMs (Online Figure VI). There 
were no significant differences between tagged and untagged 
hiPSC-CMs. Next, we assessed with the 3 different fluores-
cent tags altered contractility. SarcTrack analyses of TTN-
GFP, MYOM1-RFP, and ACTN-2-mApple, hiPSC-CMs 
showed comparable contractility and relaxation durations 
(Figure 3A and 3B; Online Movie II): 9.6±0.3% and 99±4 
ms (TTN-GFP); 10±0.3% and 97±4 ms (MYOM1-RFP); 
and 9.3±0.4% and 109±5 ms (ACTN-2-mApple). Multiple 
independent differentiations of the TTN-GFP and MYOM1-
RFP, hiPSC-CMs were also studied to assess experimental 
variance among biological replicates. The variance was low 
across replicates for sarcomere shortening, resting SLs, con-
traction durations, and relaxation durations (Online Figure 
VIIA through VIID). The Z-disc labeled TTN-GFP and 
M-line labeled MYOM1-RFP, hiPSC-CM lines were func-
tionally equivalent for percent contractility and relaxation 
durations but showed minimal differences (P=0.04) in con-
traction duration and resting SL. Transcriptional analyses of 
fluorescently tagged and untagged hiPSC-CMs showed no 
significant differences (Online Figure VIII).
We quantified sarcomere content of hiPSC-CM using 
SarcTrack to assess maturation during differentiation days 12 
to 20. After the initial rapid growth of sarcomeres, the con-
tent was stable through day 40 (Table 1). Contractile param-
eters (Figure 3C through 3F; Table 1) showed that sarcomere 
shortening increased from 6.9±0.8% at day 12 to a plateau 
of 9.3±0.4% by day 20. Relaxation duration shortened from 
204±23 ms at day 12 to 99±8.7 ms by day 20. By differentia-
tion day 20, contractile parameters plateaued (Figure 3C and 
Figure 2. Comparison of SarcTrack with existing methods of sarcomere tracking and computational benchmarking of SarcTrack with simulated 
z-disc pairs. A, Simulated sarcomeres produced using a custom MatLab code define adjustable synthetic sarcomeres that can be altered for distances 
between Z-discs and contraction rates. B, Fitting of simulated sarcomeres by SarcTrack showing the goodness of initial fitting using the algorithm, where 
the colored bar indicates the relative stretch of the wavelet fit with pink being longer sarcomeres and blue shorter. C and D, This shows ground truth and 
computed curves of distances for 8 synthetic movies. gt is the ground truth distance curve. The numbers after gt are the proportions of contraction vs 
relaxation times. For example, gt (1, 2) means relaxation takes twice as long as contraction, and in gt (2, 2) both contraction and relaxation are twice the 
values in gt (1, 1). The number in parenthesis after avg fit is the number of sarcomeres tracked. The avg fit curves are the average of the curves of distances 
measured for individual sarcomeres (registered to handle lack of synchronicity). E, A frame showing an unpatterned human induced pluripotent stem 
cell–derived cardiomyocyte (hiPSC-CM) at 100X magnification, where red lines indicate sarcomeres selected for fast Fourier transform (FFT) analysis. FFT 
analysis tracks the periodicity of many linearly arranged sarcomeres, which is problematic in unpatterned hiPSC-CMs, because of cellular irregularities and 
nonlinearly arranged sarcomeres. For FFT analyses, the user must manually define regions of interest in each movie, which is inefficient, labor intensive, 
and can introduce selection bias. FFT provides reliable measures of maximum and minimum sarcomere length, as the signal becomes noisy when aligned 
sarcomeres number <10–20. F, In comparison SarcTrack wavelet labeling of sarcomeres is automated and selects all sarcomeres in a field of view by 
parametric thresholding as described in Figure 1. SarcTrack labels individual sarcomeres irrespective of orientation and is fully automated once parameters 
are predefined for a batch of movies. SarcTrack can provide sarcomere length as well as contraction and relaxation durations and beat rate. G, Graph 
showing data analysis of sarcomere shortening from 3 movies that were analyzed by both FFT analysis and SarcTrack analysis. Plotted dots represent a 
single FFT measure in FFT analysis (derived from red lines shown in A) or a single-tracked sarcomere in SarcTrack analysis. SarcTrack provided on average 
across 3 samples 100-fold more data points, in an automated analysis. H, Graph showing the data analysis of sarcomere shortening when cells are treated 
with 1 μmol/L MYK-461 reducing cellular contractility. No significant differences were observed when the 2 techniques were statistically compared against 
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3E), after which there was little variance in these parameters 
(Figure 3D and 3F).
We also performed parametric analyses of contractile 
properties in paced and unpaced day 30 TTN-GFP hiPSC-
CMs (Figure 4A through 4F; Table 2). Sinusoidal fitting of 
contractile cycles defined the mean endogenous beat rate of 
hiPSC-CMs at 39.9±1.7 bpm compared with cells paced at 1 
Hz (59.3±0.2 bpm). Beat rate had a substantial impact on con-
tractility parameters. Contraction time (Figure 4A) in unpaced 
cells was 146±8 ms compared with 314±6 ms in paced cells. 
Relaxation time (Figure 4B) of unpaced cells was 130±6 ms 
compared with paced cells 330±8 ms. Beating rate had less in-
fluence on contracted SLs than on relaxed SLs (Figure 4C and 
4D). Sarcomere shortening was 11.3±0.16% in paced cells 
and 10.3±0.26% in unpaced cells (Figure 4E).
SarcTrack also provided an estimate of the electric ad-
herence to pacing across a cell population (Figure 4F; Online 
Movie III), and readily identified cells without electric adher-
ence to pacing (typically <5%). Notably, with the exclusion of 
relaxation times, pacing reduced the SEM for each contractile 
Figure 3. SarcTrack assessment of sarcomere function in human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) with different 
fluorescent tags and throughout differentiation. A, Sarcomere shortening as a percentage of initial sarcomere length, studied at day 30 of differentiation 
in hiPSC-CM lines with 3 different fluorescent tags labeling the sarcomere Z-disc or M-line. B, Relaxation duration (time to peak relaxation after peak 
contraction) of hiPSC-CM lines. In A and B, circles denote microscopic field of view, each containing ≈200 sarcomeres. Composite data includes ≈10 000 
sarcomeres. There were no statistical differences (denoted as NS) in sarcomere shortening or relaxation durations between hiPSC-CMs with distinct 
fluorescent tags. C, Sarcomere shortening measured in hiPSC-CMs at differentiation days 12 to 40. D, The mean SEM of sarcomere contractility as a 
function of differentiation day. Sarcomere contractility had less variability postdifferentiation day 20 (reduced SEM). E, Relaxation duration as a function 
of differentiation days. Relaxation duration decreased with differentiation day and was stabilized by day 20. F, The mean and SEM of relaxation duration 
decreased with differentiation days and plateaued by day 20. These data infer that hiPSC-CM analyses at day 30 of differentiation should minimize variability. 
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parameter, thereby highlighting the utility of acute pacing dur-
ing SarcTrack data acquisition, so as to reduce divergent beat 
rates among unpaced hiPSC-CMs.
We compared contractility of TTN-GFP hiPSC-
CMs after acute exposure to pharmacological agents us-
ing SarcTrack (Figure 5A through 5D; Online Figure IX; 
Online Movies IV and V), including the allosteric myosin 
ATPase inhibitor, MYK-46128 and the myosin activator, CK-
1827452. These molecules produced dose-dependent and 
reciprocal changes in sarcomere shortening (Figure 5A). 
CK-1827452 caused a dose-dependent increase in contrac-
tility from 8.3±0.3% to 12.9±0.6%, except at high dose (10 
Table 1. Contractile Parameters Measured Over the Differentiation Time Course
 D12 D15 D20 D25 D30 D35 D40
Mean sarcomere count 21±3.5 50±5.1 396±29 428±24 517±25 446±26 560±14
Contractility, % 6.9±0.8 8.8±0.4 9.3±0.4 9.4±0.2 9.1±0.2 9.5±0.3 9.3±0.3
Relaxation duration, ms 204±23 112±10 99±8.7 100±5.7 133±6.0 89±5.5 109±7.6
Data from 3 separate differentiations is provided with the mean and SEM of the sarcomere counts per field of view (100X 
microscopy), contractility percentage, and relaxation duration. D indicates day postdifferentiation.
Figure 4. Effects of electrical pacing on TTN-GFP human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) contractile 
parameters assessed by SarcTrack. A, Histogram showing the number of observations as a function of contraction time in paced (gray, 1 Hz stimulation) 
and unpaced (green) hiPSC-CMs. B, Relaxation time as a function of pacing status. C, Contracted sarcomere length (SL) as a function of pacing. D, Relaxed 
SL as a function of pacing. E, Sarcomere shortening as a function of pacing. F, Beat rate as a function of pacing. TTN-GFP hiPSC-CMs were studied at 
day 30 of differentiation. Observation denotes the mean data from one field of view (≈200 sarcomeres). Histograms were generated from 122 unpaced and 
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μmol/L) there was a paradoxical depression (7.2±0.6%), 
presumably an indication of dose-dependent toxicity. Low 
concentration (≤2 μmol/L) of CK-1827452 had little effect 
on the duration of contraction and relaxation but high doses 
decreased the duration of contraction (Figure 5B and 5C). 
MYK-461 decreased sarcomere shortening and increased 
the duration of both contraction and relaxation in hiPSC-
CMs. Both CK-1827452 and MYK-461 reduced endoge-
nous beating rates (Figure 5D).
Parallel analyses of commonly used cardiac drugs that in-
directly modulate cardiomyocyte contractility showed distinct 
effects on sarcomere performance (Figure 5E through 5H). 




 adrenergic receptors, 
reduced beat rates similar to CK-1827452 but also reduced 
sarcomere shortening, with minimal effects on durations of 
contraction and relaxation, except at high doses. Verapamil, 
which blocks voltage-dependent calcium channels, reduced 
sarcomere shortening as did MYK-461, but with minimal ef-
fects on the durations of contraction and relaxation, except at 
high doses.
To determine whether SarcTrack could detect the effects 
of human genetic variants, we engineered a heterozygous 
truncation of myosin-binding protein C (MyBPCt/+; Figure 6A 
and 6B) into TTN-GFP hiPSCs. This variant recapitulates the 
genotype of many patients with hypertrophic cardiomyopathy 
(HCM).29,30 After differentiation into hiPSC-CMs, MyBPC 
(myosin-binding protein C) protein levels were reduced by 
44% (P=0.01) of normal (Figure 6C and 6D), demonstrating 
haploinsufficiency. SarcTrack data from day 30 isogenic wild-
type and MyBPCt/+ hiPSC-CMs, across multiple differentia-
tions (Figure 6E through 6H; Online Movie VI), demonstrated 
that the HCM variant increased cellular shortening (12.4% 
versus 9.8%; P=0.0001) and slowed relaxation (140 ms ver-
sus 87 ms; P<0.0001). These in vitro phenotypes recapitulate 
the human cardiac manifestations of HCM: hypercontractility 
and impaired relaxation.29,31 MYK-461 treatment of mutant 
hiPSC-CMs reversed these abnormalities, restoring function 
comparable to in vivo responses observed in HCM mice car-
rying myosin mutations28 (Figure 6G and 6H). SarcTrack data 
indicated that low dose (1 μmol/L) MYK-461 normalized 
hypercontractility, whereas higher doses (2–4 μmol/L) were 
needed to normalize relaxation.
Discussion
We demonstrate that SarcTrack, a MatLab algorithm, effi-
ciently measures contractile parameters of hundreds of in-
dividual sarcomeres from a single movie, and enables rapid 
evaluation of sarcomere function from a single 5-second 
movie. The algorithm is optimized to handle nonlinearly ar-
ranged sarcomeres in hiPSC-CMs, as each sarcomere is inde-
pendently assessed. By capturing multiple videos and fields of 
view, the method simultaneously provides a data set that in-
cludes thousands of sarcomere measurements per experimen-
tal condition—a scale of data that has never been achieved 
with previous methodologies that assess sarcomere perfor-
mance. SarcTrack is adaptable for analyses of sarcomere and 
muscle physiology, studies of human gene variants, and as-
sessments of both desirable and unintended effects of pharma-
cological agents on contractility.
The underlying technique used in SarcTrack is a simu-
lated sarcomere, which we defined by a set of 6 parameters 














Unpaced 146±89 130±62 1.71±0.04 1.93±0.003 10.3±2.9 40±19
Paced (1 Hz) 315±67 330±84 1.71±0.03 1.9±0.005 11.3±1.7 60±2
All data are presented as mean±SEM of 3 biological replicates. SL indicates sarcomere length.
Figure 5. SarcTrack assessment of contractile effects of 
pharmacological agents. A–D, Plots of contractile parameters assessed 
by SarcTrack in day 30 TTN-GFP human induced pluripotent stem 
cell–derived cardiomyocytes (hiPSC-CMs) varied with dose-dependent 
increases of CK-1827452 (myosin activator) or MYK-461 (myosin inhibitor). 
Dotted lines denote the mean of untreated samples, which served as 
controls. E–H, Plots of hiPSC-CMs contractile parameters derived 
from SarcTrack demonstrate dose-dependent effects of verapamil and 
propranolol. For each panel, ≈10 fields of view were assessed per drug 
concentration for each of 3 independent differentiations of hiPSC-CMs. 
Significances are denoted as *P<0.05, **P<0.01, and ***P<0.001. All values 
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and then iteratively fitted to each individual sarcomere in a 
video frame. The algorithm tracked changes in SL through-
out each frame of a movie to define sarcomere displace-
ment, and provided measures of peak contracted and peak 
relaxed SLs, percent contraction, relaxation duration, con-
traction duration, and beat rate for each sarcomere. Users 
define and test settings for sarcomere fitting (as described in 
Online Methods), after which subsequent analyses are fully 
automated. Computational processing of each video requires 
on 15 minutes and occurs without user input and once movie 
data are collected, downstream analyses are rapid, unbiased, 
and user-friendly. SarcTrack software can be combined with 
the plethora of existing methodologies used to visualize sar-
comeres, so that the algorithm can be widely applicable to re-
searchers from multiple disciplines of muscle biology.
Figure 6. MyBPC (myosin-binding protein C) haploinsufficiency modeled in TTN-GFP human induced pluripotent stem cell–derived cardiomyocytes 
(hiPSC-CMs) and studied by SarcTrack. A, Guide RNA used to target exon-2 of MYBPC3 in TTN-GFP hiPSC-CMs for CRISPR/Cas9 mutagenesis. B, 
Schematic representation of the excision of 8 nucleotides resulting in a premature stop codon (*) in exon-2. C, Western blot of MyBPC protein and β-actin 
obtained from 3 independent differentiations of wild-type (WT) and MyBPC mutant TTN-GFP hiPSC-CMs at differentiation day 30. D, MyBPC protein 
normalized to β-actin expression in WT and MyBPC mutant hiPSCs demonstrates 50% reduction of MyBPC protein content. E and F, SarcTrack analyses of 
heterozygous MyBPCt/+ TTN-GFP hiPSC-CMs and isogenic controls (nucleofected with CRISPR-Cas9 but without MYBCP3 guides) showed indistinguishable 
beat rates of 36±1.4 ms, but MyBPCt/+ TTN-GFP hiPSC-CMs had increased sarcomere contractility and prolonged relaxation. G and H, The allosteric myosin 
inhibitor MYK-461 caused dose-dependent reduction in contractility and improved relaxation in MyBPCt/+ TTN-GFP hiPSC-CMs, highlighting SarcTrack as an 
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We benchmarked SarcTrack by studying synthetic sarco-
meres with asymmetrical contraction and compared it with 
an existing FFT analysis platform.14 We demonstrated that 
SarcTrack provided superior accuracy in measured contrac-
tility of Z-disc pairs and more robust and rapid functional as-
sessment of sarcomeres in hiPSC-CMs.
Using SarcTrack, we showed that the contractile param-
eters in hiPSC-CMs with different fluorescent tags are indis-
tinguishable, and we provided functional data during stages 
of hiPSC-CM differentiation and maturation. In response to 
pharmacological perturbations that directly (CK-1827452 and 
MYK-461) or indirectly (verapamil and propranolol) modu-
lated sarcomere function, we observed therapeutic and car-
diotoxic effects on contractile parameters. SarcTrack analyses 
of hiPSC-CMs with a heterozygous truncation of MyBPC re-
vealed prototypic clinical manifestations of human HCM.31 
Application of MYK-461 to mutant hiPSC-CMs abated these 
phenotypes, evidencing that the potential therapeutic efficacy 
of this molecule in human HCM patients.
Limitations in the SarcTrack platform included the need 
for fluorescent labeled, paired domains of sarcomeres in cells 
without high levels of background signal. Fluorescent labeling 
allows precise tracking of individual sarcomeres, at far higher 
resolution than can be achieved by bright-field techniques.11,12 
However, if fluorescent labeling is not feasible, the SarcTrack 
algorithm could be trained to define sarcomere periodicity us-
ing second harmonics originating from the myosin rod α-helix, 
which can be assessed using second harmonic generation mi-
croscopy. Input videos must provide ≥30 frames per second 
with good signal-to-noise ratio. We used a relatively low frame 
rate of 30 frames per second to demonstrate that the algorithm 
can be applied in conjunction with fluorescence confocal mi-
croscopes that are not capable of obtaining high frame rate 
videos, thus extending the utility of this algorithm to those that 
do not possess more expensive imaging modalities. SarcTrack 
code can sequentially analyze individual videos on a person-
alized computer, however, researchers may prefer to perform 
simultaneous analyses of 4 or more videos, which may require 
a dedicated computational hub. Finally, as with all cell-based 
platforms, the viability and overall health of cells can impact 
data. Despite these issues, the level of precision achieved for 
analyzing sarcomere dynamics and the versatility to multiplex 
this platform with existing technologies such as traction force 
microscopy,4 multidimensional patterning techniques,32,33 and 
engineered multicellular tissues5,7 allows SarcTrack to define 
deeper insights into contractile mechanics including subtle ef-
fects on sarcomere structure and contractility in response to 
genetic variants and small molecules.
In summation, SarcTrack enables rapid evaluation of sar-
comere contractile function. The platform is optimized for 
hiPSC-CMs but can be readily adapted to other myocyte types. 
With modern cardiovascular research transitioning from basic 
mechanistic discoveries to therapeutic applications, we expect 
that novel method such as SarcTrack will further accelerate 
translational cardiovascular medicine.
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